PE20170471A1 - Polipeptidos receptores formulados y metodos relacionados - Google Patents

Polipeptidos receptores formulados y metodos relacionados

Info

Publication number
PE20170471A1
PE20170471A1 PE2016002711A PE2016002711A PE20170471A1 PE 20170471 A1 PE20170471 A1 PE 20170471A1 PE 2016002711 A PE2016002711 A PE 2016002711A PE 2016002711 A PE2016002711 A PE 2016002711A PE 20170471 A1 PE20170471 A1 PE 20170471A1
Authority
PE
Peru
Prior art keywords
formulated
related methods
receptor polypeptides
polypeptide
composition
Prior art date
Application number
PE2016002711A
Other languages
English (en)
Inventor
Ramil Latypov
Christopher Michael Haqq
Original Assignee
Santa Maria Biotherapeutics Inc
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa Maria Biotherapeutics Inc, Amgen Inc filed Critical Santa Maria Biotherapeutics Inc
Publication of PE20170471A1 publication Critical patent/PE20170471A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se refiere a una composicion que comprende una solucion de una proteina que comprende un polipeptido con una secuencia de aminoacidos SEQ ID NO: 4, 6, 12 y 14, un tampon tal como fosfato de sodio, un tensioactivo tal como polisorbato 20 y un excipiente tal como sacarosa, donde dicho polipeptido es capaz de ligarse a miostatina, activina A o GDF-11. Dicha composicion es util en el tratamiento de caquexia
PE2016002711A 2014-06-13 2015-06-15 Polipeptidos receptores formulados y metodos relacionados PE20170471A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462012104P 2014-06-13 2014-06-13
US201462047995P 2014-09-09 2014-09-09
US201462058789P 2014-10-02 2014-10-02
US201562142812P 2015-04-03 2015-04-03

Publications (1)

Publication Number Publication Date
PE20170471A1 true PE20170471A1 (es) 2017-05-14

Family

ID=54834575

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016002711A PE20170471A1 (es) 2014-06-13 2015-06-15 Polipeptidos receptores formulados y metodos relacionados

Country Status (19)

Country Link
US (1) US20170202909A1 (es)
EP (1) EP3155008B1 (es)
JP (1) JP2017519009A (es)
KR (1) KR20170035891A (es)
CN (1) CN107074931A (es)
AP (1) AP2016009647A0 (es)
AU (1) AU2015274293A1 (es)
BR (1) BR112016029211A2 (es)
CA (1) CA2952231A1 (es)
CL (1) CL2016003191A1 (es)
EA (1) EA201692568A1 (es)
IL (1) IL249373A0 (es)
MX (1) MX2016016281A (es)
PE (1) PE20170471A1 (es)
PH (1) PH12016502479A1 (es)
SG (1) SG11201610432UA (es)
TN (1) TN2016000551A1 (es)
TW (1) TW201625675A (es)
WO (1) WO2015192127A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5261187B2 (ja) 2005-11-23 2013-08-14 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａアンタゴニストおよび骨成長を促進するための使用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
TWI480048B (zh) 2007-02-01 2015-04-11 Acceleron Pharma Inc 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TWI548647B (zh) 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
CN104548056B (zh) 2007-02-09 2022-09-09 阿塞勒隆制药公司 活化素-actriia拮抗剂和促进癌症患者骨骼生长的用途
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
PT3494986T (pt) 2008-08-14 2020-07-14 Acceleron Pharma Inc Armadilhas para gdf
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
EP2440576A4 (en) 2009-06-08 2013-11-20 Acceleron Pharma Inc PROCESS FOR INCREASING THE NUMBER OF THERMOUS ADIPOCYTES
KR20120028358A (ko) 2009-06-12 2012-03-22 악셀레론 파마 인코포레이티드 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
WO2014071158A1 (en) 2012-11-02 2014-05-08 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
CA2899889A1 (en) 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
EP3154566B1 (en) 2014-06-13 2022-08-03 Acceleron Pharma Inc. Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia
SI3286206T1 (sl) 2015-04-22 2021-07-30 Biogen Ma Inc. Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase
CN110430890A (zh) 2016-11-10 2019-11-08 科乐斯疗法公司 激活素受体iia型变体及其使用方法
EP3679945A4 (en) * 2017-09-07 2021-06-16 JCR Pharmaceuticals Co., Ltd. AQUEOUS PHARMACEUTICAL COMPOSITION
US11484573B2 (en) 2017-11-09 2022-11-01 Keros Therapeutics, Inc. Activin receptor type IIa variants and methods of use thereof
EP3737406A4 (en) 2018-01-12 2021-11-03 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE IIB VARIANTS AND THEIR METHODS OF USE
CA3108920A1 (en) * 2018-08-29 2020-03-05 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
NZ512105A (en) 1998-11-13 2004-04-30 Immunex Corp Human TSLP DNA and polypeptides
JP4038118B2 (ja) 2002-11-29 2008-01-23 株式会社コガネイ 流体圧シリンダ
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
TWI573802B (zh) * 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
NZ621174A (en) * 2008-01-15 2015-09-25 Abbvie Deutschland Powdered protein compositions and methods of making same
EP2370463B1 (en) * 2008-11-26 2016-08-31 Amgen Inc. A stabilized variant of activin iib receptor
RU2600847C2 (ru) * 2010-05-10 2016-10-27 Интас Биофармасьютикалс Лимитед Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
CA2899889A1 (en) * 2013-02-01 2014-08-07 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
WO2016205370A1 (en) * 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins

Also Published As

Publication number Publication date
AP2016009647A0 (en) 2016-12-31
US20170202909A1 (en) 2017-07-20
EA201692568A1 (ru) 2017-05-31
EP3155008B1 (en) 2020-08-26
EP3155008A4 (en) 2018-05-16
JP2017519009A (ja) 2017-07-13
WO2015192127A2 (en) 2015-12-17
EP3155008A2 (en) 2017-04-19
BR112016029211A2 (pt) 2018-01-30
SG11201610432UA (en) 2017-01-27
IL249373A0 (en) 2017-02-28
WO2015192127A3 (en) 2016-03-17
CL2016003191A1 (es) 2017-11-10
CN107074931A (zh) 2017-08-18
PH12016502479A1 (en) 2017-04-10
TW201625675A (zh) 2016-07-16
KR20170035891A (ko) 2017-03-31
AU2015274293A1 (en) 2017-02-02
MX2016016281A (es) 2017-03-31
TN2016000551A1 (en) 2018-04-04
CA2952231A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
PE20170471A1 (es) Polipeptidos receptores formulados y metodos relacionados
PE20170908A1 (es) VARIANTES DE INTERFERON a2b
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
CL2016001405A1 (es) A peptide mixture
PE20170665A1 (es) Anticuerpos anti-tau humanizados
MX2018004503A (es) Receptores de antigeno quimerico anti-cd30.
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
BR112018011008A2 (pt) agonistas de cnp de liberação controlada com ligação a npr-c baixa
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
EA201691429A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
PE20131065A1 (es) Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular
MX2017003121A (es) Formulaciones de anticuerpos.
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
PH12017501205A1 (en) Glucagon derivatives
PE20161406A1 (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
PH12015500890A1 (en) Vaccine for preventing porcine edema disease
EA202090563A1 (ru) Анти-pacap антитело
CY1123219T1 (el) Βελτιωμενα αντισωματα αλφα v βητα 8

Legal Events

Date Code Title Description
FA Abandonment or withdrawal